Holen Sie sich die Stockscreener-App
29.15
0.66%
0.19
Handel nachbörslich:
29.15
Schlusskurs vom Vortag:
$28.96
Offen:
$29.05
24-Stunden-Volumen:
809.29K
Relative Volume:
1.00
Marktkapitalisierung:
$25.53B
Einnahmen:
$5.81B
Nettoeinkommen (Verlust:
$412.00M
KGV:
31.01
EPS:
0.94
Netto-Cashflow:
-
1W Leistung:
+1.82%
1M Leistung:
+1.85%
6M Leistung:
+13.29%
1J Leistung:
+15.08%
1-Tages-Spanne:
$28.89
$29.27
1-Wochen-Bereich:
$28.55
$29.27
52-Wochen-Spanne:
$23.69
$31.72
Smith Nephew Plc Adr Stock (SNN) Company Profile
Firmenname
Smith Nephew Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie SNN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNN
Smith Nephew Plc Adr
|
29.15 | 12.65B | 5.81B | 412.00M | 0 | 0.94 |
|
ABT
Abbott Laboratories
|
133.57 | 231.29B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.17 | 157.07B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.86 | 146.67B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.74 | 104.07B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.10 | 44.71B | 5.54B | 4.18B | 623.10M | 7.00 |
Smith Nephew Plc Adr Stock (SNN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-25 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-03-12 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-06 | Herabstufung | Berenberg | Buy → Hold |
| 2024-11-01 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-07-24 | Eingeleitet | Deutsche Bank | Buy |
| 2024-06-05 | Hochstufung | UBS | Neutral → Buy |
| 2023-11-28 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2023-11-03 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-10-31 | Hochstufung | HSBC Securities | Hold → Buy |
| 2023-10-13 | Eingeleitet | Stifel | Hold |
| 2023-08-08 | Hochstufung | UBS | Sell → Neutral |
| 2023-04-27 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-12 | Eingeleitet | Citigroup | Buy |
| 2022-11-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-07-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-03-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-04 | Hochstufung | Redburn | Sell → Neutral |
| 2021-06-09 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-18 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-12-01 | Eingeleitet | Barclays | Overweight |
| 2020-07-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-11-21 | Eingeleitet | Citigroup | Buy |
| 2019-11-12 | Eingeleitet | Bernstein | Outperform |
| 2019-07-23 | Hochstufung | Berenberg | Hold → Buy |
| 2019-02-08 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2019-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-11-01 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-25 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-12-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-10-11 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-27 | Herabstufung | Goldman | Buy → Neutral |
| 2017-01-19 | Eingeleitet | HSBC Securities | Hold |
| 2016-12-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2016-10-06 | Herabstufung | Berenberg | Buy → Hold |
| 2016-02-26 | Eingeleitet | Cantor Fitzgerald | Hold |
Alle ansehen
Smith Nephew Plc Adr Aktie (SNN) Neueste Nachrichten
Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense - GlobeNewswire Inc.
Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹ - The Globe and Mail
Smith & Nephew plc ADR [SNN] Investment Appeal on the Rise - knoxdaily.com
TRI (Thomson-Reuters Corp) may reap gains as insiders became active recently - knoxdaily.com
Glaukos Corporation (GKOS) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Smith+Nephew reports solid Q1 2025 growth - Investing.com
Smith & Nephew Q1 2025 slides: steady growth amid China headwinds, guidance affirmed - Investing.com
AN Stock Sees Surge of Approximately 3.05% in Last Five Days - knoxdaily.com
Smith+Nephew schedules Q1 2025 trading report release - Investing.com
UBS cuts Smith & Nephew stock rating to Neutral, sets GBP1.25 target - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
FTSE 100 up; Smith & Nephew surges; BAE gets UK defence boost - Investing.com UK
SNN (Smith & Nephew plc ADR) may reap gains as insiders became active recently - Knox Daily
Wound Closure Market Size to Hit USD 26.63 Billion by 2032, Growing at a CAGR of 6.47% - GlobeNewswire Inc.
Goldman Downgrades Riskified Ltd (RSKD) to a Sell from a Neutral - Knox Daily
Smith+Nephew to announce 2024 full year results February 25 - Investing.com
Smith+Nephew appoints new Non-Executive Director - Investing.com
Endoprosthesis Market Size to Surpass USD 60.39 Billion by 2032 at a CAGR of 9.86% - GlobeNewswire Inc.
Weekly Upgrades and Downgrades - InvestorPlace
Smith & Nephew Sees Challenges in China Market - Morningstar
Smith+Nephew, JointVue partner on ultrasound-based surgical planning for surgical robotics - Mass Device
Smith+Nephew launches new Legion knee system - Mass Device
South Korea Surgical Navigation Systems Market Size & Outlook, 2030 - Grand View Research
The Best Healthcare Stocks to Buy - Morningstar
Smith & Nephew Aligns Director Fees with Shares - TipRanks
China Surgical Navigation Systems Market Size & Outlook, 2030 - Grand View Research
Japan Surgical Navigation Systems Market Size & Outlook, 2030 - Grand View Research
Smith+Nephew launches Total Ankle patient-matched guides - Mass Device
Smith+Nephew wins FDA nod for hip system compatible with Cori surgical robot - Mass Device
Europe First Aid Market Size & Outlook, 2023-2030 - Grand View Research
Smith+Nephew launches pre-op planning tech for surgical robotics - Mass Device
Healthcare Sector - Morningstar
Here’s Why You Should Invest in Smith & Nephew plc (SNN) - Yahoo Finance
Smith+Nephew rolls out new chronic wound treatment tech - Mass Device
Smith+Nephew sales are up 7% as 12-point plan progresses - Mass Device
Smith+Nephew unveils expanded sports medicine portfolio - Mass Device
Study backs Smith+Nephew Regeneten bioinductive rotator cuff implant - Mass Device
Validea Detailed Fundamental AnalysisSNN - Nasdaq
Smith+Nephew launches hip arthroplasty system in India - Mass Device
Smith+Nephew unveils handheld digital tensioning device for robotic knee surgery - Mass Device
Zimmer Biomet Holdings Inc. stock outperforms market on strong trading day - MarketWatch
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Zimmer Biomet Holdings Inc. stock rises Monday, outperforms market - MarketWatch
Zimmer Biomet Holdings Inc. stock rises Friday, still underperforms market - MarketWatch
Zimmer Biomet Holdings Inc. stock falls Tuesday, underperforms market - MarketWatch
Zimmer Biomet Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Zimmer Biomet Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Zimmer Biomet Holdings Inc. stock rises Tuesday, outperforms market - MarketWatch
Finanzdaten der Smith Nephew Plc Adr-Aktie (SNN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):